Armenia vs Israel: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Armenia
0.1%
in 2024
Israel
0.1%
in 2024
Armenia rank
134th
Israel rank
134th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Armenia
- Israel
How they compare
Armenia currently reports 0.1% against 0.1% in Israel, a difference of 0.0%.
Across all 10 years both countries report, Israel has been ahead every year.
Armenia ranks 134th and Israel ranks 134th of 246 countries.
Israel has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Armenia | Israel | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.3% | 0.1% | Israel |
| 2020s | 0.1% | 0.1% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Armenia or Israel?
- Armenia, at 0.1% against 0.1% in Israel as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Armenia and Israel?
- 0.0%, with Armenia ahead.
- How many years of comparable data are there for Armenia and Israel?
- 10 years are reported by both, from 2015 to 2024.
- How do Armenia and Israel rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Armenia ranks 134th and Israel ranks 134th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.